Frontier
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Obstet Gynecol. Nov 10, 2013; 2(4): 80-86
Published online Nov 10, 2013. doi: 10.5317/wjog.v2.i4.80
Individualized misoprostol dosing for labor induction or augmentation: A review
Shi-Yann Cheng
Shi-Yann Cheng, Department of Obstetrics and Gynecology, China Medical University Beigang Hospital, Yunlin County 65152, Taiwan
Author contributions: Cheng SY solely contributed to this paper.
Correspondence to: Shi-Yann Cheng, MD, Department of Obstetrics and Gynecology, China Medical University Beigang Hospital, 123 Shinder Road, Beigang Town, Yunlin County 65152, Taiwan. shiyann.cheng@msa.hinet.net
Telephone: +886-5-7837933 Fax: +886-5-7836439
Received: March 18, 2013
Revised: June 3, 2013
Accepted: July 18, 2013
Published online: November 10, 2013
Abstract

Cesarean birth rates are greater than 20% in many developed countries. The main diagnoses contributing to the high rate of cesarean births in nulliparous women are dystocia and prolonged labor. Traditionally, a policy of vaginal dinoprostone for the treatment of unripe cervix or early amniotomy with oxytocin administration for a ripened cervix has been associated with a modest reduction in the rate of cesarean births due to arrest disorders. However, the course of vaginal dinoprostone is tedious and oxytocin should be administered through an infusion pump, which may be inconvenient in certain settings. Because misoprostol has powerful uterotropic and uterotonic effects, and has become a common agent used in the practice of obstetrics and gynecology, the United States Food and Drug Administration removed the absolute contraindication of the drug during pregnancy from its label in April 2002. However, excessive uterine contractility resulting in tachysystole or fetal distress is always a concern with the oral or vaginal use of fixed-dosage misoprostol. Therefore, misoprostol should be administered with caution to ensure that fetal hypoxia does not occur. A pilot trial examining the use of very small, frequent, titrated oral misoprostol dosages administered every 2 h was first conducted by Hofmeyr et al in 2001. Given women’s different metabolisms and responses to misoprostol, another method of titrating individualized oral misoprostol with dosing administered every hour relative to uterine response was then developed by Cheng in 2006. Based on previous studies, this titration method is potentially an ideal alternative to traditional dinoprostone, oxytocin or the previously established misoprostol dosing method for labor induction or augmentation.

Keywords: Cervix, Misoprostol, Oxytocin, Labor induction, Labor augmentation

Core tip: Avoiding uterine tachysystole and fetal hypoxia is the critical consideration when implementing labor induction or augmentation with misoprostol. Titrated oral misoprostol is potentially an ideal alternative to traditional dinoprostone, oxytocin or the previously established misoprostol dosing method for labor induction or augmentation.